© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#blood cancer

Yescarta, CAR-T, axicabtagene ciloleucel
CAR-T Therapy: Lifeline to A Cure?
Imbruvica Bests Chemotherapy for Older People With Leukemia
Blood Cancers 101
Sonia Dolinger

Youngish With Cancer

Sonia Dolinger runs a meal delivery business and fundraises for cancer research. She has chronic lymphocytic leukemia.

Stem Cell Transplant (Bone Marrow Transplant)

FDA Approves New Sarclisa Regimen for Multiple Myeloma

The monoclonal antibody reduces the risk of disease progression or death by 45%.
Chimeric antigen receptor T-cell (CAR-T) therapy

FDA Approves New CAR-T Therapy for Multiple Myeloma

More than 70% of people treated with Abecma, a customized immunotherapy, experienced complete or partial remission.

Cancer Patients and Transplant Recipients Need Both COVID-19 Vaccine Doses

Natural immunity and vaccine responses may be weaker in people with immune suppression, so they should get their second dose promptly.

How One Molecule Involved in Most Leukemias May Lead to Targeted Therapies

Researchers have identified another molecule that may lead to the development of more effective targeted medications.
Heidi Yates

A Cancer You Can’t Cut Out

Heidi Yates, who has chronic lymphocytic leukemia, has the grit it takes to fight for a good life with chronic blood cancer.

Survey Finds COVID-19 Vaccine Hesitancy Among Those With Blood Cancer

The reluctance comes despite serious risk of COVID-19 complications for people with blood cancers such as leukemia and lymphoma.
Multiple myeloma cells

FDA Approves Pepaxto for Heavily Treated Multiple Myeloma

Nearly a quarter of patients treated with the peptide-drug conjugate experienced partial remission.
Chimeric antigen receptor T-cell (CAR-T) therapy

What’s Next for T-cell Therapies: Q&A with Dr. Stanley Riddell

After approval of the latest cellular therapy for non-Hodgkin lymphoma, the big challenge is how to extend it to common solid tumors.

FDA Approves Ukoniq for Marginal Zone and Follicular Lymphoma

Umbralisib led to remission in 49% of patients with marginal zone lymphoma and 43% of those with follicular lymphoma.

People With Cancer Should Receive COVID-19 Vaccine, Experts Say

The coronavirus vaccines are safe and should be effective even for people with advanced cancer.
Aaron L. Moye, PhD

Damon Runyon’s Top 2020 Highlights in Cancer Research

Damon Runyon Cancer Research Foundation shares some exciting discoveries made by Damon Runyon researchers in 2020.
Myeloma cells (purple) in a patient's bone marrow, with a few normal cells in pink in the background.

FDA Approves Xpovio for Refractory or Relapsed Multiple Myeloma

Xpovio (selinexor) was approved for adults with multiple myeloma who have received at least one prior therapy.

COVID-19 and Cancer Treatment

Studies ask whether cancer treatment, such as chemotherapy and immunotherapy, can lead to more severe COVID-19.

Among Minorities, Poverty Raises Death Risk From Acute Myeloid Leukemia

Poorer outcomes for Black and Hispanic patients significantly depend on where they live.
Advertisement
Science News
Features